STAT Plus: In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments
The Aduhelm Files
This investigative series explores the science, money and politics behind the approval of the Alzheimer’s drug aducanumab. Read to learn more about this controversial drug and its implications for the future of Alzheimer’s treatment.
Latest
STAT Plus: FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
STAT Plus: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol
STAT Plus: Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds